AU2009246402B2 - Pyrrolopyridines as kinase inhibitors - Google Patents

Pyrrolopyridines as kinase inhibitors Download PDF

Info

Publication number
AU2009246402B2
AU2009246402B2 AU2009246402A AU2009246402A AU2009246402B2 AU 2009246402 B2 AU2009246402 B2 AU 2009246402B2 AU 2009246402 A AU2009246402 A AU 2009246402A AU 2009246402 A AU2009246402 A AU 2009246402A AU 2009246402 B2 AU2009246402 B2 AU 2009246402B2
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
phenyl
compound
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009246402A
Other languages
English (en)
Other versions
AU2009246402A1 (en
Inventor
James F. Blake
Mark Chicarelli
Indrani W. Gunwardana
Yvan Le Huerou
Michael Lyon
Peter J. MOHR
Eli M. Wallace
Bin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009246402(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AU2009246402A1 publication Critical patent/AU2009246402A1/en
Application granted granted Critical
Publication of AU2009246402B2 publication Critical patent/AU2009246402B2/en
Priority to AU2013218743A priority Critical patent/AU2013218743B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009246402A 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors Ceased AU2009246402B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013218743A AU2013218743B2 (en) 2008-05-13 2013-08-19 Pyrrolopyridines as kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
US61/052,926 2008-05-13
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013218743A Division AU2013218743B2 (en) 2008-05-13 2013-08-19 Pyrrolopyridines as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2009246402A1 AU2009246402A1 (en) 2009-11-19
AU2009246402B2 true AU2009246402B2 (en) 2013-05-23

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009246402A Ceased AU2009246402B2 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Country Status (30)

Country Link
US (6) US8178131B2 (enExample)
EP (2) EP2990407B1 (enExample)
JP (2) JP5703212B2 (enExample)
KR (2) KR101643426B1 (enExample)
CN (3) CN102089307B (enExample)
AR (1) AR071717A1 (enExample)
AU (1) AU2009246402B2 (enExample)
BR (1) BRPI0913580B8 (enExample)
CA (1) CA2724262C (enExample)
CL (1) CL2009001152A1 (enExample)
CO (1) CO6321244A2 (enExample)
CR (1) CR11803A (enExample)
CY (1) CY1116692T1 (enExample)
DK (1) DK2307409T3 (enExample)
ES (1) ES2552643T3 (enExample)
HK (1) HK1219950A1 (enExample)
HR (1) HRP20151018T1 (enExample)
HU (1) HUE026160T2 (enExample)
IL (1) IL209258A (enExample)
MX (1) MX2010012449A (enExample)
NZ (1) NZ589318A (enExample)
PH (1) PH12013501779B1 (enExample)
PL (1) PL2307409T3 (enExample)
PT (1) PT2307409E (enExample)
RS (1) RS54358B1 (enExample)
RU (1) RU2517194C2 (enExample)
SI (1) SI2307409T1 (enExample)
TW (2) TWI458727B (enExample)
UA (1) UA111933C2 (enExample)
WO (1) WO2009140320A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
EP2242757B1 (en) 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
KR101676062B1 (ko) * 2009-04-11 2016-11-14 어레이 바이오파마 인크. Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
BR112013003864B1 (pt) 2010-08-20 2021-08-31 Hutchison Medipharma Limited Compostos de pirrolpirimidina, composição e uso dos mesmos
CN108721284A (zh) 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
MX339899B (es) 2011-02-25 2016-06-16 Array Biopharma Inc Compuestos de triazolopiridina como inhibidores de pim cinasa.
JP2014516941A (ja) 2011-04-29 2014-07-17 アムジェン インコーポレイテッド Ｐｉｍ阻害剤としての二環式ピリダジン化合物
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
RU2635359C2 (ru) * 2012-04-23 2017-11-13 Дженентек Инк. Промежуточные химические соединения и способы получения соединений
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
RU2675814C2 (ru) 2013-09-25 2018-12-25 Вертекс Фармасьютикалз Инкорпорейтед 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
WO2017003090A1 (ko) 2015-06-30 2017-01-05 서울바이오시스 주식회사 Uv led가 적용된 포충기
TW202510883A (zh) * 2015-11-04 2025-03-16 德商默克專利有限公司 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
TWI873098B (zh) * 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
CN119798252A (zh) * 2023-10-09 2025-04-11 中国石油化工股份有限公司 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法
TW202617721A (zh) * 2024-06-14 2026-05-01 美商騰維療法股份有限公司 化合物、組成物及方法
TW202604487A (zh) * 2024-06-18 2026-02-01 大陸商南京正大天晴製藥有限公司 五員并六員雜環化合物及用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE217309T1 (de) 1993-10-14 2002-05-15 Abbott Lab Verbindungen des chinolizinon-typs
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
US7514448B2 (en) * 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
BRPI0608659A2 (pt) 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
JP2008545660A (ja) * 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
AU2006285915B2 (en) * 2005-08-30 2011-02-24 Asahi Kasei Pharma Corporation Sulfonamide compound
PE20070543A1 (es) 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
WO2007125321A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
WO2009061781A1 (en) 2007-11-07 2009-05-14 Schering Corporation Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
WO2009089352A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
EP2242757B1 (en) * 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
CN108721284A (zh) 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors

Also Published As

Publication number Publication date
TWI458727B (zh) 2014-11-01
JP2015098482A (ja) 2015-05-28
CN109942575A (zh) 2019-06-28
DK2307409T3 (en) 2015-09-21
PT2307409E (pt) 2015-11-04
EP2307409B1 (en) 2015-08-12
US20110070317A1 (en) 2011-03-24
RS54358B1 (sr) 2016-04-28
CA2724262C (en) 2017-08-15
CN102089307A (zh) 2011-06-08
EP2307409A1 (en) 2011-04-13
EP2990407A1 (en) 2016-03-02
BRPI0913580A2 (pt) 2015-10-20
PL2307409T3 (pl) 2016-01-29
RU2517194C2 (ru) 2014-05-27
HUE026160T2 (en) 2016-05-30
NZ589318A (en) 2011-06-30
CO6321244A2 (es) 2011-09-20
CN102089307B (zh) 2015-07-01
EP2990407B1 (en) 2019-10-16
US9365568B2 (en) 2016-06-14
CN104926810A (zh) 2015-09-23
KR20110008102A (ko) 2011-01-25
HK1152035A1 (en) 2012-02-17
UA111933C2 (uk) 2016-07-11
CN104926810B (zh) 2019-02-19
JP2011520896A (ja) 2011-07-21
US8545897B2 (en) 2013-10-01
SI2307409T1 (sl) 2015-11-30
PH12013501779B1 (en) 2019-02-13
CR11803A (es) 2011-02-11
US8178131B2 (en) 2012-05-15
WO2009140320A1 (en) 2009-11-19
CY1116692T1 (el) 2017-03-15
IL209258A (en) 2017-01-31
US20130045286A1 (en) 2013-02-21
PH12013501779A1 (en) 2014-08-27
KR20140093266A (ko) 2014-07-25
IL209258A0 (en) 2011-01-31
ES2552643T3 (es) 2015-12-01
JP5703212B2 (ja) 2015-04-15
BRPI0913580B1 (pt) 2020-03-10
US8981085B2 (en) 2015-03-17
HRP20151018T1 (hr) 2015-10-23
US9969727B2 (en) 2018-05-15
US8758830B2 (en) 2014-06-24
RU2010150786A (ru) 2012-06-20
CL2009001152A1 (es) 2009-10-16
MX2010012449A (es) 2011-05-25
TW201002707A (en) 2010-01-16
BRPI0913580B8 (pt) 2021-05-25
KR101657856B1 (ko) 2016-09-19
US20140100369A1 (en) 2014-04-10
KR101643426B1 (ko) 2016-07-27
US20150322061A1 (en) 2015-11-12
CA2724262A1 (en) 2009-11-19
TW201529573A (zh) 2015-08-01
US20160368916A1 (en) 2016-12-22
AR071717A1 (es) 2010-07-07
HK1219950A1 (en) 2017-04-21
TWI554512B (zh) 2016-10-21
US20140243520A1 (en) 2014-08-28
AU2009246402A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
US9969727B2 (en) Pyrrolopyridines as kinase inhibitors
TWI851747B (zh) 介導酪氨酸激酶2活性的雜環化合物
CA3259960A1 (en) HETEROCYCLIC UREA AND AMIDE COMPOUNDS AS JAK2 INHIBITORS
AU2013218743B2 (en) Pyrrolopyridines as kinase inhibitors
HK1152035B (en) Pyrrolopyridines as kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired